Merck Serono has signed a license agreement with the Spanish National Cancer Research Centre (CNIO) in Madrid for cancer drug development. The global agreement will build on CNIO’s research discoveries to develop and commercialize new oncology compounds.   Merck was granted exclusive rights to new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase, as well as a screening platform to validate the compounds, in exchange for an upfront payment and potential payments totaling €19 ...